April 23, 2021

Hyperthermic Intraperitoneal Chemotherapy with Cisplatin and Paclitaxel Improves Progression-Free Survival Compared with Cisplatin Alone

Combination improves outcomes without increasing postoperative morbidity

HIPEC_650x450

Despite recent advances in medical and surgical techniques used to treat epithelial ovarian cancer (EOC), significant mortality remains. Because of ongoing treatment challenges, trials that demonstrate extended overall survival for patients with advanced EOC are encouraging, including a recent study suggesting that hyperthermic intraperitoneal chemotherapy (HIPEC) using a combination of cisplatin and paclitaxel is associated with significantly improved progression free survival (PFS) compared with single-agent cisplatin. The results of this Cleveland Clinic study were presented at the annual meeting of the Society for Gynecologic Oncology.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

HIPEC combination doubles progression free survival

In this prospective study, patients (N = 54) were included if they responded to neoadjuvant chemotherapy and, following debulking surgery, received HIPEC with cisplatin or paclitaxel for stage III or IV high-grade EOC from 2017 to 2020. Patients were given either cisplatin alone (80-100mg/m2 for 90 minutes; n = 28 [51.9%]) or paclitaxel (135-175mg/m2 for 90 minutes) with cisplatin (80-100mg/m2 for 45 minutes; n = 26 [48.1%]) in a perfusate of normal saline at 41-43C degrees for 90 minutes. Within the cohort, there were no significant differences between patient groups in terms of demographics, operating time, comorbidities, disease stage or postoperative adverse events.

The mean PFS for the entire cohort was 15.7 months. When stratified by HIPEC regimen, however, a significant difference emerged. Patient who received a combination of cisplatin and paclitaxel had a mean PFS of 22.2 months compared with 10.9 months for patients receiving cisplatin alone.

“We were hoping we’d see a difference, but didn’t expect it to be at this magnitude – essentially doubling progression free survival,” says first author Laura Chambers, DO. “Additionally, we found no significant differences in mild, moderate or severe postoperative complications, no difference in length of stay and no difference in time to chemotherapy. There was a slight trend toward increased ICU admission with the combination therapy, but it wasn’t statistically significant.”

Advertisement

Despite the limitations of sample size, use of a prospective registry from a single institution and the possibility of selection bias, overall the study was received well by gynecologic oncologists, according to Robert DeBernardo, MD, section head of Gynecologic Oncology at Cleveland Clinic’s Ob/Gyn & Women’s Health Institute. “We hope it will inform future studies.”

“There are several questions that still need to be answered about HIPEC,” Dr. DeBernardo says. “What is the right regimen? Who is the optimal patient? When do we give it? Many of the studies our group has undertaken in the last few years have been aimed at answering those questions. Ideally, we would like to conduct a prospective randomized trial, but that takes time. In the meantime, we are in the process of assembling a multi-institutional consortium with other institutions that do HIPEC in an effort to increase the number of patients included in studies.”

Ovarian cancer research is desperately needed

Although rare, ovarian cancer remains one of the leading causes of cancer-related death in the U.S., where the rate of new cases of ovarian cancer is 11.2 per 100,000, with a death rate of 6.7 per 100,000. That’s 21,000 new cases of ovarian cancer each year. With a 5-year relative survival of 49.1%, the prognosis is generally poor: ovarian cancer accounts for nearly 14,000 deaths. The median age at diagnosis is 63 years old, and risk factors include older age, early menarche or late menopause, nulliparity, endometriosis and genetic predisposition.

Advertisement

Related Articles

Dr. Jagadeesh at Cleveland Clinic
February 28, 2024
Treating Patient with Systemic T-Cell Lymphoma and Graft-Versus-Host Disease

A case study on the value of access to novel therapies through clinical trials

Doctor measuring patient's waist size
February 26, 2024
Impact of Obesity on GVHD & Transplant Outcomes in Hematologic Malignancies

Findings highlight an association between obesity and an increased incidence of moderate-severe disease

Physician with patient
February 21, 2024
Strategies for Improving Clinical Trial Equity

Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access

How antibody drug conjugates work
February 13, 2024
Real-World Use of Trastuzumab Deruxtecan

Key learnings from DESTINY trials

CQD-4445459-rotz-650×450
February 7, 2024
Advances in Bone Marrow Transplant Have Improved Outcomes in Fanconi Anemia

Overall survival in patients treated since 2008 is nearly 20% higher than in earlier patients

CQD-CHP4445461-hanna-sickle-650×450
February 5, 2024
Haploidentical Bone Marrow Transplant Has Durable Engraftment in Patients With Sickle Cell Disease

Two-year event-free survival comparable to matched sibling donor myeloablative transplant

24-CNR-4545611-CQD-Podcast-967×544
February 1, 2024
Possibilities of CRISPR Technology (Podcast)

Gene editing technology offers promise for treating multiple myeloma and other hematologic malignancies, as well as solid tumors

CQD-CHP4445460-hanna-sickle-650×450
January 30, 2024
Gene Therapy Trials Show Positive Results in Sickle Cell Disease and Thalassemia

First-in-human trials of CRISPR-Cas12a gene editing demonstrate safety and meaningful event-free survival

Ad